Lung functions among patients with pulmonary tuberculosis in Dar es Salaam - A cross-sectional study

BMC Pulmonary Medicine

Volumn 16, Issue 1, 2016, Pages

  Manji, Mohamed ^a   Shayo, Grace ^a   Mamuya, Simon ^a   Mpembeni, Rose ^a   Jusabani, Ahmed ^b   Mugusi, Ferdinand ^a  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b Aga Khan Hospital   (Tanzania)

Author keywords

Obstruction; Restriction; Spirometry; TB sequlae

Indexed keywords

ADULT; AGE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LUNG FUNCTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; QUALITY OF LIFE; RECURRENT INFECTION; SOCIOECONOMICS; SPIROMETRY; TANZANIA; ADOLESCENT; CLINICAL TRIAL; FOLLOW UP; FORCED EXPIRATORY VOLUME; INCIDENCE; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPUTUM; TUBERCULOSIS, PULMONARY; VITAL CAPACITY; YOUNG ADULT;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SPIROMETRY; SPUTUM; TANZANIA; TUBERCULOSIS, PULMONARY; VITAL CAPACITY; YOUNG ADULT;

EID: 85007453720     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-016-0213-5     Document Type: Article

References (48)

1. WHO. The Global Burden of Disease 2004 Update. WHO. 2008.
2. Miller TL, McNabb SJN, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality lost to tuberculosis. PLoS One. 2009;4:e5080.
3. Snider G, Doctor L, Demas T, Shaw A. Obstructive airway disease in patients with treated pulmonary tuberculosis. Am Rev Respir Dis. 1971;103(5):625-40.
4. Birath G, Caro J, Malmberg R, Simonsson BG. Airways obstruction in pulmonary tuberculosis. Scand J Respir Dis. 1966;47:27-36.
5. Lancaster JF, Tomashefski JF. Tuberculosis-a cause of emphysema. Am Rev Respir Dis. 1963;87:435-7.
6. Plit ML, Anderson R, Van Rensburg CE, Page-Shipp L, Blott JA, Fresen JL, Feldman C. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J. 1998;12:351-6.
7. Simpson DG, Uschner M, Mcclement J. Respiratory function in pulmonary tuberculosis. Am Rev Respir Dis. 1963;87:1-16.
8. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax. 2000;55:32-8.
9. Willcox PA, Ferguson AD. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med. 1989;83:195-8.
10. Krishna K, Bond S, Artvinli M, Reid KDG, McHardy GJR, Crofton JW. Pulmonary function in treated tuberculosis; a long-term follow-up. Am Rev Respir Dis. 1977;115:402-4.
11. Vargha G. Fifteen year follow-up of lung function in obstructive and non-obstructive pulmonary tuberculosis. Acta Med Hung. 1983;40:271-6.
12. Seaton A, LA Seaton D. Crofton and Douglass's Respiratory Disease. United Kingdom: Blackwell Science; 2002.
13. WHO. Global Tuberculosis Report 2015. 2015.
14. The First National Tuberculosis Prevalence Survey in the United Republic of Tanzania Final Report. 2013.
15. Stenton C. The MRC breathlessness scale. Occup Med (Lond). 2008;58:226-7.
16. Walters JAE, Wood-Baker R, Walls J, Johns DP. Stability of the EasyOne ultrasonic spirometer for use in general practice. 2006. p. 306-10.
17. Skloot GS, Edwards NT, Enright PL. Four-Year Calibration Stability of the EasyOne Portable Spirometer. Respir Care. 2010;55:873-7.
18. Barr RG, Stemple KJ, Mesia-Vela S, Basner C, Derk S, Henneberger P, Milton DK, Taveras B. Reproducibility and Validity of a Handheld Spirometer. Respir Care. 2008;53:433-41.
19. Hallal PC, Muin A, Lopez MV, Valdivia G, Talamo C, Pertuze J. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J. 2007;30:1180-5.
20. Carlsen HK, Gislason T, Benediktsdottir B, Kolbeinsson TB, Hauksdottir A, Thorsteinsson T, Briem H. A survey of early health effects of the Eyjafjallaj�kull 2010 eruption in Iceland: a population-based study. 2012.
21. Schirnhofer L, Firlei N. Using Targeted Spirometry to Reduce Non-Diagnosed Chronic Obstructive Pulmonary Disease. Respiration. 2011;81:476-82.
22. Knudsen TM, M�rkve ODD, Mfinanga S, Hardie JONA. Predictive equations for spirometric reference values in a healthy adult suburban population in Tanzania. Tanzan J Health Res. 2011;13:1-10.
23. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J. 2005;26:319-38.
24. Chavasse R, Johnson P, Francis J, Balfour-Lynn I, Rosenthal M, Bush A. To clip or not to clip? Noseclips for spirometry. Eur Respir J. 2003;21:876-8.
25. Newall C, McCauley T, Shakespeare J, Cooper B. Is it necessary to use a noseclip in the performance of spirometry using a wedge bellows device? Chron Respir Dis. 2007;4:53-7.
26. Ferguson G, Enright P, Buist A. Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program. Chest. 2000;117:1146-61.
27. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163:1256-76.
28. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, Van Der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, Macintyre N, Mckay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948-968.
29. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis. Chest. 2007;131:1817-24.
30. Lee JH, Chang JH. Lung function in patients with chronic airflow obstruction due to tuberculous destroyed lung. Respir Med. 2003;97:1237-42.
31. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med. 2007;101:1163-70.
32. Konietzko NF, Carton RW, Leroy EP. Causes of death in patients with bronchiectasis. Am Rev Respir Dis. 1969;100:852-8.
33. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, Flower CD, Bilton D, Keogan MT. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162(4 Pt 1): 1277-84.
34. Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter R. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest. 1995;108:955-61.
35. Escombe AR, Moore DAJ, Gilman RH, Pan W, Navincopa M, Ticona E, Mart�nez C, Caviedes L, Sheen P, Gonzalez A, Noakes CJ, Friedland JS, Evans CA. The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med. 2008;5:e188.
36. Calderon EJ, Rivero L, Respaldiza N, Morilla R, Montes-Cano MA, Friaza V, Munoz-Lobato F, Varela JM, Medrano FJ, de la Horra C. Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease Who Are Colonized with Pneumocystis jiroveci. Clin Infect Dis. 2007;45:e17-9.
37. Ehrlich RI, White N, Norman R, Laubscher R, Steyn K, Lombard C, Bradshaw D. Predictors of chronic bronchitis in South African adults. Int J Tuberc Lung Dis. 2004;8:369-76.
38. Caballero A, Torres-Duque CA, Jaramillo C, Bol�var F, Sanabria F, Osorio P, Orduz C Guevara DP, Maldonado D. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133:343-9.
39. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J. 1999;13:1109.
40. Rona RJ, Gulliford MC, Chinn S. Effects of prematurity and intrauterine growth on respiratory health and lung function in childhood. BMJ. 1993;306:817-20.
41. National Bureau of Statistics: Tanzania in Figure 2014. Dar es Salaam. 2015.
42. UNICEF. Children and Women in Tanzania. 2010.
43. Lee SW, Kim YS, Kim D-S, Oh Y-M, Lee S-D. The risk of obstructive lung disease by previous pulmonary tuberculosis in a country with intermediate burden of tuberculosis. J Korean Med Sci. 2011;26:268-73.
44. Cooper AM. Cell mediated immune responses in Tuberculosis. Annu Rev Immunol. 2009;27:393-422.
45. Swaminathan S, Narendran G, Menon PA, Padmapriyadarsini C, Arunkumar N, Sudharshanam NM, Kumar SR, Chandrasekhar S, Swaminathan S. Impact of HIV Infection on Radiographic Features in Patients with Pulmonary Tuberculosis. Indian J Chest Dis Allied Sci. 2007;49:133-6.
46. Weis SE, Miller TL, Hilsenrath PE, Moonan PK. Comprehensive cost description of tuberculosis care. Int J Tuberc Lung Dis. 2005;9:467.
47. Miller TL, Reading JA, Hilsenrath P, Weis SE. What are the costs of suspected but not reported tuberculosis? Ann Epidemiol. 2006;16:777-81.
48. Pasipanodya JG, McNabb SJ, Hilsenrath P, Bae S, Lykens K, Vecino E, Munguia G, Miller TL, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health. 2010;10:259.